• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    CAS No. 66-97-7 Price $30 / 20mg
    Catalog No.CFN97142Purity>=98%
    Molecular Weight186.2 Type of CompoundCoumarins
    FormulaC11H6O3Physical DescriptionPowder
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • VIB Department of Plant Systems ... (Belgium)
  • Tohoku University (Japan)
  • Instituto de Investigaciones Agr... (Chile)
  • University of Canterbury (New Zealand)
  • University of Otago (New Zealand)
  • Research Unit Molecular Epigenet... (Germany)
  • University of Malaya (Malaysia)
  • Johannes Gutenberg University Ma... (Germany)
  • John Innes Centre (United Kingdom)
  • University of Toronto (Canada)
  • University of Madras (India)
  • More...
  • Package
    Featured Products
    Przewaquinone A

    Catalog No: CFN92022
    CAS No: 76843-23-7
    Price: $463/5mg
    Tanshinone IIB

    Catalog No: CFN99820
    CAS No: 17397-93-2
    Price: $463/5mg
    Dihydrocucurbitacin B

    Catalog No: CFN92140
    CAS No: 13201-14-4
    Price: $418/5mg

    Catalog No: CFN92377
    CAS No: 638-95-9
    Price: $318/5mg

    Catalog No: CFN92252
    CAS No: 510-22-5
    Price: $463/5mg
    Biological Activity
    Description: Psoralen is a naturally occurring furocoumarin that intercalates with DNA, inhibiting DNA synthesis and cell division. Psoralen has immunomodulatory properties on Th2 response in vitro, it can remit the degeneration of lumbar intervertebral disc induced by IL-1β to some extent, and affect the related factors of IL-1β signaling pathway. Psoralen may be feasible for reversing the multidrug resistance by inhibiting ABCB1 gene and protein expression. Psoralen ultraviolet A is an effective treatment for psoriasis.
    Targets: IL Receptor | HIV | EGFR | ABCB1 | GATA-3
    In vitro:
    Phytomedicine. 2014 Jun 15;21(7):970-7.
    Psoralen reverses docetaxel-induced multidrug resistance in A549/D16 human lung cancer cells lines.[Pubmed: 24703328]
    Chemotherapy is the recommended treatment for advanced-stage cancers. However, the emergence of multidrug resistance (MDR), the ability of cancer cells to become simultaneously resistant to different drugs, limits the efficacy of chemotherapy. Previous studies have shown that herbal medicine or natural food may be feasible for various cancers as potent chemopreventive drug. This study aims to explore the capablility of reversing the multidrug resistance of docetaxel (DOC)-resistant A549 cells (A549/D16) of Psoralen and the underlying mechanisms.
    In this study, results showed that the cell viability of A549/D16 subline is decreased when treated with Psoralen plus DOC, while Psoralen has no effect on the cell proliferation on A549 and A549/D16 cells. Furthermore, mRNA and proteins levels of ABCB1 were decreased in the presence of Psoralen, while decreased ABCB1 activity was also revealed by flow cytometry. Based on these results, we believe that Psoralen may be feasible for reversing the multidrug resistance by inhibiting ABCB1 gene and protein expression.
    Such inhibition will lead to a decrease in ABCB1 activity and anti-cancer drug efflux, which eventually result in drug resistance reversal and therefore, sensitizing drug-resistant cells to death in combination with chemotherapeutic drugs.
    Pak J Pharm Sci. 2015 Mar;28(2 Suppl):667-70.
    Effects of psoralen on chondrocyte degeneration in lumbar intervertebral disc of rats.[Pubmed: 25796142]
    Discuss the internal mechanism of delaying degeneration of lumber intervertebral disc.
    The cartilage of lumbar intervertebral disc of SD rats was selected in vitro, then cultured by tissue explant method, and identified by HE staining, toluidine blue staining and immunofluorescence. The optimal concentration of Psoralen was screened by cell proliferation assay and RT-PCR method. The cells in third generation with good growth situation is selected and placed in 6-well plate at concentration of 1×10(5)/well and its expression was tested. Compared to concentration of 0, the mRNA expression of Col2al (Collagen Ⅱ) secreted by was up regulated chondrocyte of lumbar intervertebral disc at the concentration of 12.5 and 25μM (P<0.0 or P<0.01). The aggrecan mRNA of Psoralen group was higher than blank control group (P<0.01); compared with IL-1β induced group, the mRNA expression of Col2al was significantly increased but the mRNA expression of ADAMTS-5 was significantly decreased in Psoralen group (P<0.01).
    These findings suggest that, Psoralen can remit the degeneration of lumbar intervertebral disc induced by IL-1β to some extent, and affect the related factors of IL-1β signaling pathway.
    In vivo:
    Int J Nanomedicine. 2014 Jan 23;9:669-78.
    Evaluation of psoralen ethosomes for topical delivery in rats by using in vivo microdialysis.[Pubmed: 24489470]
    This study aimed to improve skin permeation and deposition of Psoralen by using ethosomes and to investigate real-time drug release in the deep skin in rats.
    We used a uniform design method to evaluate the effects of different ethosome formulations on entrapment efficiency and drug skin deposition. Using in vitro and in vivo methods, we investigated skin penetration and release from Psoralen-loaded ethosomes in comparison with an ethanol tincture. In in vitro studies, the use of ethosomes was associated with a 6.56-fold greater skin deposition of Psoralen than that achieved with the use of the tincture. In vivo skin microdialysis showed that the peak concentration and area under the curve of Psoralen from ethosomes were approximately 3.37 and 2.34 times higher, respectively, than those of Psoralen from the tincture. Moreover, it revealed that the percutaneous permeability of ethosomes was greater when applied to the abdomen than when applied to the chest or scapulas.
    Enhanced permeation and skin deposition of Psoralen delivered by ethosomes may help reduce toxicity and improve the efficacy of long-term Psoralen treatment.
    Psoralen Description
    Source: The seeds of Psoralea corylifolia L.
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds
    Decursitin D

    Catalog No: CFN95002
    CAS No: 245446-61-1
    Price: $388/5mg
    Arnicolide C

    Catalog No: CFN91996
    CAS No: 34532-67-7
    Price: $398/5 mg
    Lappaol F

    Catalog No: CFN95069
    CAS No: 69394-17-8
    Price: $368/10mg
    Mulberroside F

    Catalog No: CFN90794
    CAS No: 193483-95-3
    Price: $398/10mg
    3,6'-Disinapoyl sucrose

    Catalog No: CFN90578
    CAS No: 139891-98-8
    Price: $138/20mg

    Catalog No: CFN95012
    CAS No: 35214-83-6
    Price: $338/5mg

    Catalog No: CFN95073
    CAS No: 164163-92-2
    Price: $333/5mg

    Catalog No: CFN95026
    CAS No: 166021-14-3
    Price: $388/10mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.
    doi: 10.1016/j.phymed.2017.12.030.

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 5.3706 mL 26.8528 mL 53.7057 mL 107.4114 mL 134.2642 mL
    5 mM 1.0741 mL 5.3706 mL 10.7411 mL 21.4823 mL 26.8528 mL
    10 mM 0.5371 mL 2.6853 mL 5.3706 mL 10.7411 mL 13.4264 mL
    50 mM 0.1074 mL 0.5371 mL 1.0741 mL 2.1482 mL 2.6853 mL
    100 mM 0.0537 mL 0.2685 mL 0.5371 mL 1.0741 mL 1.3426 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Kinase Assay:
    Proc Natl Acad Sci U S A. 1986 Nov;83(21):8211-5.
    Psoralens potentiate ultraviolet light-induced inhibition of epidermal growth factor binding.[Pubmed: 3490664 ]
    The Psoralens, when activated by ultraviolet light of 320-400 nm (UVA light), are potent modulators of epidermal cell growth and differentiation. Previously, we reported that, in mammalian cells, these compounds bind to specific saturable high-affinity cellular receptor sites.
    In the present studies, we demonstrate that binding of Psoralens to their receptors followed by UVA light activation is associated with inhibition of epidermal growth factor (EGF) receptor binding. Inhibition of EGF binding, which required UVA light, was rapid and dependent on the dose of UVA light (0.5-2.0 J/cm2), as well as the concentration of Psoralens (10 nM to 1 microM). Higher doses of UVA light (2.0-6.0 J/cm2) by themselves were also inhibitory, indicating that Psoralens potentiate the UVA-induced inhibition of EGF binding. A number of biologically active analogs of Psoralen, including 8-methoxyPsoralen, 5-methoxyPsoralen, and 4,5',8-trimethylPsoralen, when activated by UVA light, were found to be inhibitors of binding. Inhibition of EGF binding by Psoralens was observed in a variety of human and mouse cell culture lines known to possess Psoralen receptors. In the epidermal-derived line PAM 212, at least two populations of receptors with different affinities for EGF were found. Psoralens and UVA light selectively inhibited binding to the higher-affinity EGF receptors, an effect analogous to that of the phorbol ester tumor promoters. As observed with phorbol esters, photoactivated Psoralens appeared to inhibit EGF binding by an indirect mechanism.
    These data demonstrate that the Psoralens and UVA light have direct biological effects on cell-surface membranes. Since EGF is a growth-regulatory peptide, the ability of Psoralens and UVA light to inhibit EGF binding may underlie the biologic effects of these agents in the skin.
    Animal Research:
    Am J Chin Med. 2014;42(3):665-78.
    Effects of Psoraleae fructus and its major component psoralen on Th2 response in allergic asthma.[Pubmed: 24871658]
    This study is aimed to evaluate the effects of Psoraleae fructus (PF) on Th2 responses in a rat model of asthma in vivo and Psoralen, a major constituent in PF, on Th2 responses in vitro.
    A rat model of asthma was established by sensitization and challenged with ovalbumin (OVA). Airway hyperresponsiveness was detected by direct airway resistance analysis. Lung tissues were examined for cell infiltration and mucus hypersecretion. Bronchoalveolar lavage fluid (BALF) was assessed for cytokine levels. In vitro study, Th2 cytokine production was evaluated in the culture supernatant of D10.G4.1 (D10 cells) followed by the determination of cell viability, meanwhile Th2 transcription factor GATA-3 expression in D10 cells was also determined. The oral administration of PF significantly reduced airway hyperresponsiveness (AHR) to aerosolized methacholine and decreased IL-4 and IL-13 levels in the BALF. Histological studies showed that PF markedly inhibited inflammatory infiltration and mucus secretion in the lung tissues. In vitro study, Psoralen significantly suppressed Th2 cytokines of IL-4, IL-5 and IL-13 by ConA-stimulated D10 cells without inhibitory effect on cell viability. Furthermore, GATA-3 protein expression was also markedly reduced by Psoralen.
    This study demonstrated that PF exhibited inhibitory effects on hyperresponsiveness and airway inflammation in a rat model of asthma, which was associated with the suppression of Th2 response. Psoralen, a major constituent of PF, has immunomodulatory properties on Th2 response in vitro, which indicated that Psoralen might be a critical component of PF for its therapeutic effects.
    Structure Identification:
    Nucleic Acids Res. 1996 Feb 1; 24(3): 509–514.
    Psoralen crosslinking between human immunodeficiency virus type 1 RNA and primer tRNA3(Lys).[Reference: WebLink]
    Initiation of reverse transcription is a crucial step of retroviral infection. In HIV-1, it involves hybridization of the 18 3′-terminal nucleotides of the primer tRNA3Lys to the primer binding site (PBS) of the viral RNA. Moreover, additional interactions between the two RNAs were recently evidenced [Isel et al. (1995) J. Mol. Biol. 247, 25269–25272].
    To get further information on the topology of the viral RNA/tRNA3Lys complex, we used Psoralen to induce RNA-RNA crosslinking. A defined intermolecular crosslinked complex was obtained. The crosslinked regions were characterized by RNase T1 digestion followed by bi-dimensional gel electrophoresis. The crosslinked residues (nucleotide mcm5S2U34 and U35 in the anticodon loop of tRNA3Lys and UCU154 in the viral RNA upstream of the PBS) were mapped using a retardation method coupled with random hydrolysis. The formation of this crosslink depends on the same elements that are required for the formation of the extended interactions between primer and template RNAs, i.e., the modified bases of the tRNA and a conserved A-rich loop located upstream of the PBS in the genomic RNA.
    Therefore, the present crosslinking data provide relevant information on the topology of the template/primer binary complex.